CONTINENTAL H (00513) is expected to incur a loss of no less than HK$180 million for the year.
Henghe Group (00513) issued an announcement, stating that the Group expects to achieve no less than... by the end of the fiscal year ending on June 30, 2024.
, CONTINENTAL H (00513) announced that the group is expecting a loss of no less than HK$180 million for the financial year ending on June 30, 2024, compared to a loss of approximately HK$115.4 million for the financial year ending on June 30, 2023.
Despite the reversal of impairment losses on mining rights, the expected increase in loss is primarily due to reduced revenue; net loss on disposal of properties held for sale and unrealized fair value losses on investment properties; increased financial costs; and impairment losses on goodwill, intangible assets, and right-of-use assets.
Related Articles
CENT UNIT HLDG (01959) issued 500,000 shares due to the exercise of warrants.
China Petroleum & Chemical Corporation (600028.SH) has accumulated repurchased 48.8213 million A shares, costing 270 million yuan.
Haisco Pharmaceutical (688302.SH): The Phase II clinical trial for the treatment of metabolic associated fatty liver disease (MASH) drug HP515 has completed the enrollment of the first batch of participants.
CENT UNIT HLDG (01959) issued 500,000 shares due to the exercise of warrants.
China Petroleum & Chemical Corporation (600028.SH) has accumulated repurchased 48.8213 million A shares, costing 270 million yuan.
Haisco Pharmaceutical (688302.SH): The Phase II clinical trial for the treatment of metabolic associated fatty liver disease (MASH) drug HP515 has completed the enrollment of the first batch of participants.
